169 related articles for article (PubMed ID: 35983918)
1. B-Cell depletion therapy in IgG4-related disease: State of the art and future perspectives.
Lanzillotta M; Stone JH; Della-Torre E
Mod Rheumatol; 2023 Mar; 33(2):258-265. PubMed ID: 35983918
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease.
Campochiaro C; Della-Torre E; Lanzillotta M; Bozzolo E; Baldissera E; Milani R; Arcidiacono PG; Crippa S; Falconi M; Dagna L
Eur J Intern Med; 2020 Apr; 74():92-98. PubMed ID: 31901297
[TBL] [Abstract][Full Text] [Related]
3. Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease.
Lanzillotta M; Della-Torre E; Milani R; Bozzolo E; Bozzalla-Cassione E; Rovati L; Arcidiacono PG; Partelli S; Falconi M; Ciceri F; Dagna L
Clin Exp Rheumatol; 2019; 37 Suppl 118(3):159-166. PubMed ID: 30652677
[TBL] [Abstract][Full Text] [Related]
4. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
Majumder S; Mohapatra S; Lennon RJ; Piovezani Ramos G; Postier N; Gleeson FC; Levy MJ; Pearson RK; Petersen BT; Vege SS; Chari ST; Topazian MD; Witzig TE
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1947-1953. PubMed ID: 29526692
[TBL] [Abstract][Full Text] [Related]
5. Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse.
Lanzillotta M; Della-Torre E; Milani R; Bozzolo E; Bozzalla-Cassione E; Rovati L; Arcidiacono PG; Partelli S; Falconi M; Ciceri F; Dagna L
Arthritis Res Ther; 2018 Oct; 20(1):222. PubMed ID: 30285841
[TBL] [Abstract][Full Text] [Related]
6. Development of targeted therapies in IgG4-related disease.
Nakayamada S; Tanaka Y
Mod Rheumatol; 2023 Mar; 33(2):266-270. PubMed ID: 35983919
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis.
Omar D; Chen Y; Cong Y; Dong L
Rheumatology (Oxford); 2020 Apr; 59(4):718-726. PubMed ID: 31511884
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapy options for IgG4-related disease.
Lanzillotta M; Fernàndez-Codina A; Culver E; Ebbo M; Martinez-Valle F; Schleinitz N; Della-Torre E
Expert Rev Clin Immunol; 2021 May; 17(5):471-483. PubMed ID: 33689549
[TBL] [Abstract][Full Text] [Related]
9. Therapy of immunoglonuline IgG4 related disease (IgG4-RD).
Adam Z; Dastych M; Čermák A; Doubková M; Skorkovská Š; Pour L; Řehák Z; Koukalová R; Adamová Z; Štork M; Krejčí M; Boichuk I; Král Z
Vnitr Lek; 2022; 68(E-6):15-22. PubMed ID: 36316207
[TBL] [Abstract][Full Text] [Related]
10. Clinical Perspectives on IgG4-Related Disease and Its Classification.
Katz G; Stone JH
Annu Rev Med; 2022 Jan; 73():545-562. PubMed ID: 34669430
[TBL] [Abstract][Full Text] [Related]
11. Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
Fernández-Codina A; Pinilla B; Pinal-Fernández I; López C; Fraile-Rodríguez G; Fonseca-Aizpuru E; Carballo I; Brito-Zerón P; Feijóo-Massó C; López-Dupla M; Cid MC; Martínez-Valle F; ; ;
Joint Bone Spine; 2018 Dec; 85(6):721-726. PubMed ID: 29452298
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study.
Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L
Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis.
Lanzillotta M; Della-Torre E; Wallace ZS; Stone JH; Karadag O; Fernández-Codina A; Arcidiacono PG; Falconi M; Dagna L; Capurso G
Pancreatology; 2021 Oct; 21(7):1395-1401. PubMed ID: 34244040
[TBL] [Abstract][Full Text] [Related]
14. B cell targeted therapy for immunoglobulin G4-related disease.
Yamamoto M
Immunol Med; 2021 Dec; 44(4):216-222. PubMed ID: 33583344
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients.
Khosroshahi A; Carruthers MN; Deshpande V; Unizony S; Bloch DB; Stone JH
Medicine (Baltimore); 2012 Jan; 91(1):57-66. PubMed ID: 22210556
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on current and emerging therapies for immunoglobulin G4-related disease.
Tanaka Y; Stone JH
Mod Rheumatol; 2023 Mar; 33(2):229-236. PubMed ID: 36408992
[TBL] [Abstract][Full Text] [Related]
17. IgG4-Related Disease with Emphasis on Its Gastrointestinal Manifestation.
Vashi B; Khosroshahi A
Gastroenterol Clin North Am; 2019 Jun; 48(2):291-305. PubMed ID: 31046976
[TBL] [Abstract][Full Text] [Related]
18. Recent progress on the treatment of type 1 autoimmune pancreatitis and IgG4-related disease.
Okazaki K; Ikeura T; Uchida K
Mod Rheumatol; 2023 Mar; 33(2):237-241. PubMed ID: 35737955
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.
An W; Wu Z; Li M; Yu H; Zhao X; Wang X; Wang Y; Wang Q; Duan W; Kong Y; Ma H; Ou X; You H; Liu Y; Li P; Duan T; Jia J
Orphanet J Rare Dis; 2022 Aug; 17(1):307. PubMed ID: 35927746
[TBL] [Abstract][Full Text] [Related]
20. IgG4-related disease in a multi-ethnic community: clinical characteristics and association with malignancy.
Poo SX; Tham CSW; Smith C; Lee J; Cairns T; Galliford J; Hamdulay S; Jacyna M; Levy JB; McAdoo SP; Roufosse C; Wernig F; Mason JC; Pusey CD; Tam FWK; Tomlinson JAP
QJM; 2019 Oct; 112(10):763-769. PubMed ID: 31225617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
